Physician profile
Kavitha Hubbard
NPI 1124058805
$3,693.54
in general payments reported to CMS, 2019-2025
24 companies · $894 in 2025
The $894 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.55 · 2020: $140 · 2021: $321 · 2022: $642 · 2023: $847 · 2024: $774 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,514.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $537.88 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $471.62 | 2021-2025 | Tavneos, Krystexxa, Aranesp |
| Fresenius USA Marketing, INC. | $427.11 | 2021-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $352.91 | 2021-2025 | |
| Vifor Pharma, INC. | $298.86 | 2019-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $214.58 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $211.72 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $181.57 | 2022-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $132.16 | 2021-2023 | Lupkynis |
| Horizon Therapeutics Plc | $128.82 | 2020-2022 | |
| Ardelyx, INC. | $121.50 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $115.28 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $94.60 | 2023-2025 | |
| Glaxosmithkline, LLC. | $86.35 | 2022-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $56.85 | 2023 | Ultomiris |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $51.93 | 2025 | Vafseo |
| Novo Nordisk INC | $48.96 | 2024 | Ozempic, Wegovy |
| Kyowa Kirin, INC. | $38.50 | 2023-2025 | |
| Scpharmaceuticals INC. | $25.79 | 2025 | |
| Genzyme Corporation | $23.10 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.04 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.36 | 2025 | Purified Cortrophin Gel |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.29 | 2023 | Xifaxan |
| Opko Pharmaceuticals, LLC | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.